Business Context and Reporting Period
This Form 8-K is a current report filed by KindlyMD, Inc. (the "Company") on June 25, 2025. The filing serves as a Regulation FD disclosure regarding a corporate announcement made on the same date. The Company is an emerging growth company with its principal executive offices in Salt Lake City, Utah.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a specific event rather than a financial statement.
Material Changes
The material change disclosed in this filing is a corporate appointment:
- Executive Appointment: On June 25, 2025, Nakamoto Holdings, Inc. ("Nakamoto") and KindlyMD, Inc. announced the appointment of Andrew Creighton as Nakamoto's Chief Commercial Officer.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, management commentary on financial performance, or specific risk factors. The document explicitly states that the information furnished, including the attached press release, will not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and will not be incorporated by reference into any Securities Act filing unless specifically identified.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for details on Andrew Creighton's background and the scope of his new role.
- Confirm the relationship between KindlyMD, Inc. and Nakamoto Holdings, Inc., as the appointment pertains to Nakamoto.
- Check subsequent filings for any financial impact or strategic shifts resulting from this executive appointment.